Chi Podcasts

Jeffrey Borenstein of Draper Laboratory speaks to Cambridge Healthtech Institute on May 9, 2016. Dr. Borenstein will present during the 3D Cellular Models meeting, part of the World Preclinical Congress, June 14-17 in Boston, Massachusetts. Topics include promising methods for recapitulating the in vivo microenvironment in 3D cell culture models, microfluidic technologies for multiplexed and interacting organ models, microsystems-based approaches for organ assist devices and organ models for drug efficacy and safety testing, and Draper Lab’s resources for that research. For more information, please visit http://www.WorldPreclinicalCongress.com/

Muneesh Tewari of the University of Michigan speaks to Cambridge Healthtech Institute on April 28, 2016. Dr. Tewari will give his keynote presentation during the conference program at The Liquid Biopsy Summit, June 22-24 in San Francisco, California. Topics include circulating extracellular RNAs as a liquid biopsy approach, developing novel biomarker methods that involve serial monitoring at high-time resolution, and researching circulating microRNA biomarkers for cancer and other diseases with a diverse scientific and medical background. For more information, please visit http://www.LiquidBiopsySummit.com/

Joerg Holenz of AstraZeneca previews his in-depth course on Modern Lead Generation Strategies and highlights the important issues on this subject. Joerg will be speaking during the Mastering Medicinal Chemistry meeting, June 15-16, in Boston, MA. For more information, please visit http://www.WorldPreclinicalCongress.com/

Dr. Robert D. Bell, Principal Scientist, Integrative Neuroscience at Pfizer spoke to CHI to discuss challenges in in researching the blood-brain barrier for creating effective treatments, as well as future directions and potential research avenues. He also discussed the topics and speakers he’s excited to see at the Blood-Brain Barrier conference this June. Dr. Bell is one of our chairpeople and roundtable moderators at the Blood-Brain Barrier conference, taking place June 15-16, 2016 in Boston, MA as part of the World Preclinical Congress. For details, visit http://www.WorldPreclinicalCongress.com/Blood-Brain-Barrier/

Victoria Mosolgo interviews Dr. Tom Laue of the University of The University of New Hampshire. Dr. Laue will be giving a keynote presentation in the High-Concentration Protein Formulations track at the 8th Annual Bioprocessing Summit taking place August 15-19, 2016 in Boston. To learn more, visit http://www.BioprocessingSummit.com/

Jamie Platt of BRIDGenomics, LLC speaks to Cambridge Healthtech Institute on April 21, 2016. Dr. Platt will give her presentation during the conference program at The Liquid Biopsy Summit, June 22-24 in San Francisco, California. Topics include changes in the landscape of development and commercialization of molecular diagnostics, issues and emerging opportunities for liquid biopsy sample prep, and process/technology refinements necessary for broader, routine application of liquid biopsies. For more information, please visit http://www.LiquidBiopsySummit.com/

Dr. Cory Abate-Shen of Columbia University Medical Center speaks to CHI on April 8th , 2016. Dr. Abate-Shen will be presenting during the Preclinical Models in Oncology conference at the 2016 World Preclinical Congress, June 14-17 in Boston, MA. For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Models/

CHI recently interviewed Jonathan Hughes, Partner and Practice Lead of Outsourcing and Supply Chain Management at Vantage Partners about the evolution of Sponsor-CRO strategic partnerships to date; challenges and opportunities in forming these types of partnerships; and an outlook on how these partnerships will continue to evolve. Discussion points and questions include: 1. Can you tell us a bit about yourself and the role you play at Vantage? 2. Forming strategic alliances with CROs has not traditionally been the route sponsors have taken. Why has this changed and where are we now? Also, how have sponsors and CROs adapted over the years? 3. What are some of the unforeseen risks and benefits of moving beyond a traditional customer-vendor relationship? 4. During the upcoming Strategic Alliance Management Congress Vantage will be hosting a luncheon workshop focused on managing sponsor-CRO partnerships. Can you give us any insights as to what attendees can expect to learn during this? 5. We like to end our po

György Kosztolányi, Ph.D., President, Human Reproduction Committee of Scientific Health Council, Professor Emeritus, University of Pécs, Hungary spoke to CHI to discuss the ethical challenges of preimplantation testing as well the latest research and developments, including the potential for using extracellular DNA. He also raises questions on whether IVF babies, when they grow into adults, might view their genetic information and how we may handle this in the future. Dr. Kosztolányi is our moderator for the closing panel discussion at the Reproductive Genetic Diagnostics conference, taking place 6-7 April as part of the Molecular Diagnostics Europe event. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX/

Samantha A. Schrier Vergano of Children’s Hospital of the King’s Daughters speaks to Cambridge Healthtech Institute on February 15, 2016. Dr. Schrier Vergano will give her presentation during a shared session for the Clinical Genomics and Open Source Innovations conferences at Bio-IT World Conference & Expo, April 5-7 in Boston, Massachusetts. Topics include challenges when validating clinical utility of genetic variants, ethical quandaries of sharing genetic data in clinical settings and focusing on medical genetics with a pediatric angle. To learn more, please visit http://www.Bio-ITWorldExpo.com/

Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI. The topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.MolecularDXEurope.com/

CHI president Phillips Kuhl and Sequenom CMO Daniel Grosu discuss how Sequenom is applying new technology to address the next sets of clinical questions for non-invasive prenatal testing. To learn more, please visit http://www.MolecularDXEurope.com/

Louis Fiore of Veterans Affairs Boston Healthcare System speaks to Cambridge Healthtech Institute on February 10, 2016. Dr. Fiore will give his presentation during a shared session for the Clinical Genomics and Cancer Informatics conferences at Bio-IT World Conference & Expo, April 5-7 in Boston, Massachusetts. Topics include aggregating and reusing Electronic Health Record (EHR) data for quality improvement, discovery and validation of genomic knowledge; MAVERIC's Point of Care Research Program and Precision Oncology Program; the value of Veterans Affairs programs for clinical genomics research; and empowering clinicians to make more informed decisions for patients. To find out more, visit http://www.Bio-ITWorldExpo.com/

CHI recently interviewed Dr. Dmitry Samarsky, Senior Vice President of Technology and Global Business Development at OliX Pharmaceuticals, regarding the evolution of nucleic acid-based therapeutics; challenges within this space; recent advances in chemistry and delivery; and the greatest opportunities within this space over the next few years. Discussion questions include: 1 Given the obvious benefit of oligonucleotide therapies being able to dramatically expand target space, why haven’t they impacted the drug development landscape as much as Biologics or small Molecules? What challenges have been encountered within this field? 2 It seems as if there has be a resurgence of interest in the discovery and development of oligonucleotide therapeutics. Why do you think this is? What has changed over the past few years? 3 You are hosting a workshop during the upcoming Oligonucleotide Therapeutics and Delivery conference, providing an overview of oligonucleotide therapeutics from discovery to manufacturing. Can

Ralph Minter of MedImmune will describe his approach for phenotypic antibody screening and how it is being used to discover both novel antibodies and targets. He will discuss tips for overcoming obstacles to identifying novel targets, share advice for getting best results with phenotypic screening and describe how this work has been impacted by recent discoveries in the tumor microenvironment. For more information, please visit http://www.PEGSummit.com/

Romney Humphries, Assistant Professor, UCLA Pathology & Laboratory Medicine, Section Chief of Clinical Microbiology, David Geffen School of Medicine, University of California, Los Angeles spoke to CHI to discuss how Next-Generation Sequencing has changed the way scientists detect antimicrobial resistance as well as the challenges scienctists face moving forward. Dr. Humprhies is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the Molecular Medicine TriConference. For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/

CHI speaks with Dr. Klaus Pantel, a professor and founding director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf in Germany. In this podcast Dr. Pantel discusses the steps needed to make liquid biopsy the standard-of-care, its most promising applications, and future directions. Dr. Pantel also adds his voice to the debate over whether or not early detection is viable, and in which indications it may make the most sense. For more information, please visit http://www.MolecularDXEurope.com/

CHI chats with Dr. Raymond J. Langley, Assistant Professor, Department of Pharmacology, University of South Alabama. Dr. Langley discusses the latest research and developments in metabolomics risk analysis models for sepsis and predictive biomarkers for patient survival, as well as the current challenges in developing technology for metabolomics diagnostics for sepsis. Dr. Langley is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the . For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/

CHI chats with Bert Smeets, Ph.D., Professor, Clinical Genomics, Mitochondrial Diseases, Maastricht University Medical Center. Dr. Smeets discusses the latest research and developments on diagnosing mtDNA disease using Next-Generation Sequencing, as well as his work in developing techniques to prevent mtDNA disease transmission and developing therapeutics for those affected by mtDNA disease. Dr. Smeets is one of our speakers for the Novel Diagnostic Approaches session at the Reproductive Genetic Diagnostics conference, 6-7 April, in Lisbon. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX

Peter Luppa of the Technishe Universität in München will outline what he considers some of the greatest obstacles to implementing POC testing in the clinical setting and describe the need for quality standards. He will share advice for introducing POCT within the clinical setting and some of the most exciting applications emerging for POC and how they fit into the theranostic/health monitoring ecosystem.